Published in Diabetologia on January 01, 1986
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus | NCT00551590
Investigating the Incretin Effect in Cystic Fibrosis (IECF) | NCT01975259
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 5.06
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest (2007) 5.02
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 4.19
Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care (2007) 3.97
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest (2004) 2.11
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care (2011) 1.63
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut (2005) 1.53
Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology (2011) 1.47
Gut feelings about diabetes. Endocrinol Nutr (2012) 1.46
Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes (2010) 1.46
Global biochemical profiling identifies β-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans. Diabetes (2014) 1.42
Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes (2010) 1.40
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes (2010) 1.39
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol (2011) 1.38
Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology (2012) 1.33
Do we really know why diabetes remits after gastric bypass surgery? Endocrine (2011) 1.32
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol (2011) 1.31
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig (2010) 1.27
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes (2012) 1.26
Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care (2009) 1.25
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab (2007) 1.22
Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia (2007) 1.21
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 1.20
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev (2008) 1.18
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care (2011) 1.17
Impact of postprandial glycaemia on health and prevention of disease. Obes Rev (2012) 1.17
Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Alternat Med (2013) 1.16
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab (2016) 1.15
Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian J Endocrinol Metab (2012) 1.12
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes (2011) 1.06
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol (2011) 1.06
Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol (2010) 1.06
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest (1996) 1.05
Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg (2014) 1.04
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol (2014) 1.04
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One (2012) 1.01
Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev (2013) 1.00
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 0.99
Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol (2013) 0.99
Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. J Diabetes Investig (2012) 0.99
Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes (2009) 0.98
RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. Diabet Med (2008) 0.97
Effect of gastric bypass surgery on the incretins. Diabetes Metab (2009) 0.96
Diabetes remission after bariatric surgery: is it just the incretins? Int J Obes (Lond) (2011) 0.96
Physiology of incretins in health and disease. Rev Diabet Stud (2011) 0.95
Differential contribution of insulin and amino acids to the mTORC1-autophagy pathway in the liver and muscle. J Biol Chem (2013) 0.94
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther (2011) 0.93
Gustducin couples fatty acid receptors to GLP-1 release in colon. Am J Physiol Endocrinol Metab (2013) 0.93
Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery. Diabetes Care (2011) 0.92
Gastric stimulation for weight loss. World J Gastroenterol (2012) 0.91
Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig (2014) 0.91
Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Diabetologia (2012) 0.90
Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care (2013) 0.90
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg (2004) 0.90
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.89
T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs (2010) 0.89
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun (2015) 0.89
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal. PLoS One (2012) 0.88
Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS One (2012) 0.88
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol (2014) 0.88
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovasc Diabetol (2013) 0.87
Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? Diabetes Care (2013) 0.87
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes (2014) 0.87
Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol (2014) 0.87
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol (2012) 0.87
Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol (2012) 0.86
β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes (2014) 0.86
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol (2007) 0.86
A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.86
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud (2005) 0.86
The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia (2012) 0.85
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One (2014) 0.85
The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery. Curr Diab Rep (2014) 0.85
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract (2014) 0.85
Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. Exp Mol Med (2014) 0.85
Cyclic AMP dynamics in the pancreatic β-cell. Ups J Med Sci (2012) 0.84
The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus. Regul Pept (2013) 0.84
Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes. Br J Gen Pract (2008) 0.84
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag (2006) 0.83
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes (2010) 0.83
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes (2012) 0.83
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. PLoS One (2013) 0.82
Impact of gastric emptying to the glycemic and insulinemic responses to a 75-g oral glucose load in older subjects with normal and impaired glucose tolerance. Physiol Rep (2014) 0.82
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes - a retrospective cohort study. J Diabetes Metab Disord (2014) 0.82
Insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1. Mol Cells (2011) 0.82
β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity. J Clin Endocrinol Metab (2015) 0.81
Pancreatic regulation of glucose homeostasis. Exp Mol Med (2016) 0.81
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.81
Expression profiling identifies novel gene targets and functions for Pdx1 in the duodenum of mature mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.81
Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutr Metab (Lond) (2013) 0.81
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 5.06
Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. N Engl J Med (1997) 4.18
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology (1993) 3.98
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 3.63
Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science (2002) 3.46
Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology (1993) 2.83
Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem (2001) 2.81
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab (1986) 2.80
The incretin concept today. Diabetologia (1979) 2.18
Histopathological classification of nonantral gastric endocrine growths in man. Digestion (1988) 1.85
Varieties of disgust faces and the structure of disgust. J Pers Soc Psychol (1994) 1.77
Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion (1987) 1.73
Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol (1989) 1.72
Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion (1993) 1.71
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab (1996) 1.70
Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation (1997) 1.67
Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia (1985) 1.67
Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes (2009) 1.65
Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenterol (1974) 1.63
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 1.61
Gut hormones and diabetes mellitus. Diabetes Metab Rev (1992) 1.61
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract (2011) 1.59
Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3',5'-AMP levels and lipolysis. Naunyn Schmiedebergs Arch Pharmacol (1973) 1.56
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Gastrin and G-cells in the antral mucosa of patients with pernicious anaemia, acromegaly and hyperparathyroidism and in a Zollinger-Ellison tumour of the pancreas. Eur J Clin Invest (1971) 1.52
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med (1996) 1.51
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract (2010) 1.43
Mucosal gastrin concentration, molecular forms of gastrin, number and ultrastructure of G-cells in patients with duodenal ulcer. Gut (1976) 1.42
[Genetics of osteoporosis]. Dtsch Med Wochenschr (2003) 1.39
Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int (1996) 1.39
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia (1996) 1.37
Adenosine release from fat cells: effect on cyclic AMP levels and hormone actions. Adv Cyclic Nucleotide Res (1975) 1.36
Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3':5'-monophosphate, lipolysis, and glucose oxidation in isolated fat cells. Eur J Biochem (1974) 1.36
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion (1988) 1.34
Barriers to bicycle helmet use among children. Results of focus groups with fourth, fifth, and sixth graders. Am J Dis Child (1989) 1.33
Aetiology and pathogenesis of pancreatitis. (Current concepts). Scand J Gastroenterol Suppl (1970) 1.29
Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev (1987) 1.27
The influence of glucagon on acute experimental pancreatitis in the rat. Scand J Gastroenterol (1974) 1.26
Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia (1984) 1.23
Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik (1975) 1.22
Hypoglycaemia. 1. Insulin secreting tumours. Clin Endocrinol Metab (1976) 1.22
Liver diseases and diabetes mellitus. Prog Liver Dis (1970) 1.21
Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Hum Pathol (1975) 1.20
The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med (2001) 1.19
Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab (1989) 1.17
New developments in the incretin concept. Diabetologia (1985) 1.15
Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol (1987) 1.13
Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance. Diabetologia (1973) 1.10
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol (1995) 1.09
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr (1988) 1.09
Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion (1990) 1.09
Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia (1980) 1.08
Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol (2012) 1.08
Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion (1988) 1.08
Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia (1984) 1.07
Somatostatin and insulin release from isolated rat pancreatic islets stimulated by glucose. FEBS Lett (1976) 1.07
Inhibition of gastric secretion by calcitonin in man. Horm Metab Res (1971) 1.06
Gastric inhibitory polypeptide (GIP), gastrin and insulin: response to test meal in coeliac disease and after duodeno-pancreatectomy. Diabetologia (1976) 1.05
Somatostatin and the stomach: exocrine and endocrine aspects. Metabolism (1978) 1.04
[Calcitonin-induced inhibition of exocrine pancreatic secretion in man]. Dtsch Med Wochenschr (1971) 1.04
Studies on the antilipolytic effect of adenosine and related compounds in isolated fat cells. Naunyn Schmiedebergs Arch Pharmacol (1973) 1.02
Analysis of the inhibitory effect of biguanides on glucose absorption: inhibition of active sugar transport. Diabetologia (1971) 1.02
Mechanism of insulin resistance in CCl4-induced cirrhosis of rats. Gastroenterology (1992) 1.02
Stimulation of cyclic adenosine 3',5'-monophosphate accumulation and lipolysis in fat cells by adenosine deaminase. Naunyn Schmiedebergs Arch Pharmacol (1974) 1.01
[Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)]. Dtsch Med Wochenschr (1975) 1.01
The possible role of phospholipase A in the pathogenesis of acute pancreatitis. Scand J Gastroenterol (1969) 1.01
The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol (2001) 0.99
Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia (1978) 0.98
Adaptation of the pancreas during treatment with enzyme inhibitors in rats and man. Scand J Gastroenterol Suppl (1985) 0.98
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med (2010) 0.98
Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) (2004) 0.98
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. Am J Physiol (1991) 0.98
Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion (1982) 0.97
[Hypoglycemia factitia. A differential diagnostic significant form of hyperinsulinism]. Dtsch Med Wochenschr (1969) 0.97
Antral gastrin-producing G-cells and somatostatin-producing D-cells in different states of gastric acid secretion. Gut (1982) 0.97
Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion (1986) 0.96
Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats. Gastroenterology (1987) 0.96
Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J (2003) 0.96
Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. J Exp Med (1996) 0.96
Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology (1979) 0.95
Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. Gut (1990) 0.94
The morphological substrate of the inhibition of insulin secretion by diazoxide. Horm Metab Res (1969) 0.94
Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol (1987) 0.93